The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells.
about
Pathogenesis of RON receptor tyrosine kinase in cancer cells: activation mechanism, functional crosstalk, and signaling addictionRon receptor tyrosine kinase signaling as a therapeutic targetVariant RONΔ160 of the RON receptor tyrosine kinase promotes the growth and invasion in vitro and in vivo in gastric cancer cell lines.Vitamin D3-dependent VDR signaling delays ron-mediated breast tumorigenesis through suppression of β-catenin activity.Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.The RON receptor tyrosine kinase is a potential therapeutic target in Burkitt lymphoma.Therapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment.RON kinase isoforms demonstrate variable cell motility in normal cells.Characterization of RON protein isoforms in pancreatic cancer: implications for biology and therapeutics.Monoclonal antibody Zt/g4 targeting RON receptor tyrosine kinase enhances chemosensitivity of bladder cancer cells to Epirubicin by promoting G1/S arrest and apoptosis.Nanoparticles-mediated drug delivery approaches for cancer targeting: a review.Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics.B7-H4 enhances oncogenicity and inhibits apoptosis in pancreatic cancer cells.Hepatocyte growth factor-like protein is required for prostate tumor growth in the TRAMP mouse model.Ron and its expanding role in tumor carcinogenesis.RON Signaling Is a Key Mediator of Tumor Progression in Many Human Cancers.
P2860
Q26864275-D464B8A8-DF0D-4AD0-9FF8-2CD3846486D2Q27003295-7C9F18F6-E8BA-487E-A1FD-B59241C63E8AQ35079037-0A788FDC-E1BA-49CE-8179-58F96A33D17EQ36140785-9F7765F1-9479-4E55-BD56-0AEDCF968FBEQ36377994-991F0C13-2ADD-42E5-8B2B-FDCBB2FE98E8Q36887780-223C1716-06F9-4B26-9A32-B2FCA1562E33Q36958365-94E718E4-2BD2-4AB8-9A15-47806BC47049Q37253779-886184A1-F9CD-4E17-A105-94AB58568545Q37564619-CB827905-ADC7-4607-A284-6CF274C3AB6BQ37707571-D7FB9FA5-D04C-4F8C-B548-5245A50F9F2CQ38032893-7116FFD6-0450-418F-8D21-9FA2575C8395Q38922319-A3B509AF-266A-4395-ADE2-FA0D30A160E0Q39032726-BA1AB4E1-43EC-4514-B568-3F3D51CB3018Q39154102-41890104-8387-4BC8-BD83-2DE18F011678Q41814227-0BC30CDB-3DD0-4C5F-B12A-BCF3B9365232Q44605323-B6C1CE70-7E7A-4DB3-B5FE-F489AFF99413Q53591553-0ACC5F27-39A6-4DD1-BD9C-AC35B8B0D595
P2860
The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The monoclonal antibody Zt/f2 ...... ediated by colon cancer cells.
@ast
The monoclonal antibody Zt/f2 ...... ediated by colon cancer cells.
@en
type
label
The monoclonal antibody Zt/f2 ...... ediated by colon cancer cells.
@ast
The monoclonal antibody Zt/f2 ...... ediated by colon cancer cells.
@en
prefLabel
The monoclonal antibody Zt/f2 ...... ediated by colon cancer cells.
@ast
The monoclonal antibody Zt/f2 ...... ediated by colon cancer cells.
@en
P2093
P2860
P356
P1433
P1476
The monoclonal antibody Zt/f2 ...... ediated by colon cancer cells.
@en
P2093
Hang-Ping Yao
Ming-Hai Wang
Rui-Wen Zhang
Snehal S Padhye
Sunny Guin
Yong-Qing Zhou
P2860
P2888
P356
10.1186/1476-4598-10-82
P577
2011-07-12T00:00:00Z
P5875
P6179
1017593976